148 related articles for article (PubMed ID: 15011824)
1. Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma.
Limpaiboon T; Sripa B; Wongkham S; Bhudhisawasdi V; Chau-in S; Teerajetgul Y
Hepatogastroenterology; 2004; 51(55):25-8. PubMed ID: 15011824
[TBL] [Abstract][Full Text] [Related]
2. [Result of p53, ki-67 protein expression in cholangiocarcinoma with in situ hybridization and immunohistochemistry methods].
Wang X; Zhang J; Chen J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):57-60. PubMed ID: 12903495
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis.
Batheja N; Suriawinata A; Saxena R; Ionescu G; Schwartz M; Thung SN
Mod Pathol; 2000 Dec; 13(12):1265-8. PubMed ID: 11144921
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma.
Maehara Y; Kakeji Y; Watanabe A; Baba H; Kusumoto H; Kohnoe S; Sugimachi K
Cancer; 1999 Jan; 85(2):302-8. PubMed ID: 10023696
[TBL] [Abstract][Full Text] [Related]
5. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.
von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE
Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744
[TBL] [Abstract][Full Text] [Related]
6. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.
Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M
Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950
[TBL] [Abstract][Full Text] [Related]
7. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
8. Inverse correlation of aberrant expression of fragile histidine triad (FHIT) protein with cyclin D1 protein and prognosis in Chinese patients with cholangiocarcinoma.
Zhao P; Lu Y; Zhong M; Liu L; Li B
Acta Oncol; 2008; 47(8):1557-63. PubMed ID: 18618300
[TBL] [Abstract][Full Text] [Related]
9. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
10. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm.
Nakanishi Y; Zen Y; Kondo S; Itoh T; Itatsu K; Nakanuma Y
Hum Pathol; 2008 Aug; 39(8):1153-61. PubMed ID: 18495210
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.
Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY
Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857
[TBL] [Abstract][Full Text] [Related]
12. Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers.
Itoi T; Shinohara Y; Takeda K; Takei K; Ohno H; Ohyashiki K; Yahata N; Ebihara Y; Saito T
Gastrointest Endosc; 2000 Sep; 52(3):380-6. PubMed ID: 10968854
[TBL] [Abstract][Full Text] [Related]
13. Methods in pathology. p53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections.
Terada T; Shimizu K; Izumi R; Nakanuma Y
Mod Pathol; 1994 Feb; 7(2):249-52. PubMed ID: 8008749
[TBL] [Abstract][Full Text] [Related]
14. [Serum anti-p53 antibodies in gastric cancer patients].
Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma.
Nozoe T; Yasuda M; Honda M; Inutsuka S; Korenaga D
Hepatogastroenterology; 2007; 54(77):1422-5. PubMed ID: 17708268
[TBL] [Abstract][Full Text] [Related]
16. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
17. [Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system].
Maass JD; Gottschlich S; Lippert BM; Niemann AM; Görögh T; Werner JA
Laryngorhinootologie; 1996 Jan; 75(1):53-6. PubMed ID: 8851121
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression.
Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies.
Bielicki D; Karbowniczek M; Sulzyc-Bielicka V; Kładny J; Boer C; Marlicz K; Domagała W
Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530
[TBL] [Abstract][Full Text] [Related]
20. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
